文献速递中药与中成药合理使用中医内科

多组学研究揭示黄芪中芒柄花黄素抗结直肠癌机制

Multi-omics study of the anti-colorectal cancer mechanisms of formononetin in Hedysari Radix.
PubMed 文献 · Front Pharmacol · 2026-01-06

本研究采用代谢组学、网络分析、蛋白质组学、磷酸化蛋白质组学和分子对接等多组学策略,鉴定黄芪代谢物并探究芒柄花黄素抗结直肠癌机制。在8种炮制黄芪产品中鉴定出1292种代谢物,芒柄花黄素衍生代谢物在炮制中显著富集,并鉴定出194个潜在靶点、291个差异表达蛋白和1535个磷酸化蛋白。CA9和MME被一致鉴定为关键靶点,分子对接证实与芒柄花黄素强结合,且富集于PI3K-Akt、Hippo、HIF-1信号和胆固醇代谢等癌症相关通路。

要点

  • 芒柄花黄素是黄芪炮制过程中显著富集的活性代谢物。
  • CA9和MME被多组学分析一致鉴定为芒柄花黄素的关键靶点。
  • 芒柄花黄素通过PI3K-Akt、Hippo、HIF-1信号和胆固醇代谢等多靶点发挥作用。

核心结论

  • 芒柄花黄素通过多靶点作用参与结直肠癌发展,为开发新的结直肠癌治疗策略奠定基础。

研究设计与样本

  • 采用整合代谢组学、网络分析、蛋白质组学、磷酸化蛋白质组学和分子对接的多组学策略。
  • 使用基于质谱的代谢组学在8种炮制黄芪产品中鉴定代谢物。
  • 在结肠癌细胞中进行无标记数据独立采集(DIA)蛋白质组学和磷酸化蛋白质组学分析。

主要发现

  • 在8种炮制黄芪产品中鉴定出1292种代谢物。
  • 芒柄花黄素衍生代谢物在黄芪炮制过程中显著富集。
  • 网络分析结合蛋白质组学和磷酸化蛋白质组学鉴定出194个潜在靶点、291个差异表达蛋白和1535个磷酸化蛋白受芒柄花黄素调控。
  • CA9和MME在不同分析中被一致鉴定为关键靶点,分子对接结果证实其与芒柄花黄素强结合。
  • 生物信息学分析显示芒柄花黄素处理显著富集PI3K-Akt、Hippo、HIF-1信号和胆固醇代谢等癌症相关通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hedysari Radix (HR), commonly known as Hong-Qi in Chinese, is a traditional Chinese herbal medicine recognized for possessing anti-inflammatory and anti-tumor properties. While the polysaccharides in HR have been extensively studied, other HR metabolites and their potential anti-tumor properties remain largely unknown. METHODS: We employed a multi-omics strategy integrating metabolomics, network analysis, proteomics, phosphoproteomics, and molecular docking to identify HR metabolites with anti-colorectal cancer (CRC) property and investigate underlying mechanisms. RESULTS: Using mass spectrometry-based metabolomics, we identified 1,292 metabolites across eight processed HR products. Key metabolites including medicarpin, formononetin, naringenin, and quercetin were validated via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Notably, formononetin-derived metabolites were significantly enriched during HR processing. The metabolite-metabolite correlation analysis revealed key compounds such as flavonoids and formononetin. Subsequent network analysis combined with label-free data-independent acquisition (DIA) proteomics and phosphoproteomics in colon cancer cells identified 194 potential targets, 291 differentially expressed proteins, and 1,535 phosphorylated proteins that were regulated by formononetin. Cell-surface enzymes carbonic anhydrase IX (CA9) and membrane metalloendopeptidase (MME) were consistently identified in different analyses as key targets, and molecular docking results confirmed their strong binding to formononetin. Bioinformatics analyses further revealed significant enrichment of cancer-associated pathways, including PI3K-Akt, Hippo, HIF-1 signaling, and cholesterol metabolism upon formononetin treatment. CONCLUSION: The findings provide novel insights into the HR metabolome and reveal the multi-targeting roles of formononetin in CRC development, laying the foundation for developing new CRC therapeutic strategies.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Rao J, Wang X, Chen T, et al. Multi-omics study of the anti-colorectal cancer mechanisms of formononetin in Hedysari Radix. Front Pharmacol. 2026. PMID: 41567641. doi:10.3389/fphar.2025.1649691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。